Avastin, a relatively new type of drug that shrinks cancerous tumors by cutting off their blood supply, can slow the growth of the most common and deadly form of brain cancer, a pilot study conducted at Duke University Medical Center has found.
A total of 373 new HIV cases were reported to the Department of Health, Hong Kong, last year, the highest annual number ever recorded. The figure represents a 19% increase on the 313 cases in the preceding year.
AstraZeneca (NYSE: AZN) announced the commencement of a new Phase III study of its new investigational once-daily orally administered drug, vandetanib (ZACTIMA(R), ZD6474).
The Texas Department of State Health Services (DSHS) is now testing “heel stick” blood samples from newborns for 26 disorders, with a 27th to be added this year.
University of Delaware researchers have developed an inexpensive, nonchlorine-based technology that can remove harmful microorganisms, including viruses, from drinking water.
A new study sheds light on the brain pathways of depression in general and in central nervous system dysfunction in SLE in particular.
“Nanotechnology has the potential to generate enormous health benefits for the more than five billion people living in the developing world,” according to Dr. Peter A. Singer, senior scientist at the McLaughlin-Rotman Centre for Global Health and Professor of Medicine at University of Toronto.
Nonsteroidal anti-inflammatory drugs may give some protection against esophageal adenocarcinoma developing from its premalignant state, Barrett?s esophagus.
A study funded by the Wellcome Trust and the Sir Halley Stewart Trust has shown that opening windows can be more effective than using mechanical ventilation at reducing the risk of transmission of airborne diseases such as tuberculosis (TB).
Threshold Pharmaceuticals, Inc. (Nasdaq: THLD), announced that a Phase 3 trial of glufosfamide did not show a statistically significant improvement in overall survival compared to best supportive care (BSC) in patients with metastatic pancreatic cancer who had relapsed after gemcitabine chemotherapy.